Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2017 Oct 4;16(12):2759–2769. doi: 10.1158/1535-7163.MCT-17-0439

Figure 5.

Figure 5

BMS-906024 enhances the anti-tumor activity of chemotherapy in vivo. NSCLC cell line- or patient-derived xenografts (PDX) were treated with vehicles, BMS-906024 (BMS906; triangles), paclitaxel or cisplatin (arrows), or the noted drug combinations as indicated in the insets. Left panels show tumor growth inhibition (TGI). Error bars represent the data range. *, P < 0.05; **, P < 0.01; ***, P < 0.001. NS, not significant. Right panels show Kaplan–Meier survival analysis of vehicles, BMS-906024, paclitaxel and BMS-906024 plus paclitaxel-treated groups in PDX-T42 and H838 xenografts (log rank test for paclitaxel vs. paclitaxel plus BMS-906024-treated groups, P < 0.0001 for both). N = 6–8 mice per group for each experiment.